Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Revive Therapeutics Ltd. C.RVV

Alternate Symbol(s):  RVVTF

Healthcare
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for rare disorders and infectious diseases. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. The Company’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the Company was granted Food and Drug Administration (FDA) orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.


CSE:RVV - Post by User

Revive Therapeutics Ltd.
Bullboard Posts
User Avatar Image
(1)
•••
Comment by Maximumon Sep 21, 2018 3:38am
38 Views
Post# 28661654

RE:RE:RE:RE:Why i bought 600 k shares

RE:RE:RE:RE:Why i bought 600 k shares
hi, i will not sell. i will buy more here. i can trade also in Frankfurt and Stuttgart, USA and Canada. Maybe i can convince my friend to invest also, he really has much more money than i have :-) but he is against cannabis in general, also because his son smokes cannabis and he does not like this... The only Problem of RVV is PR/Marketing. Nobody knows this Company. They must be on pages like technical420 and so on to attract Investors. Volumes from 100 k - 200 k shares / day are ridiculous. a guy like me can influence share Price to 0.15 or 0.25 without Problem.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities